Key result
Administration of 18F-FB-A20FMDV2 in healthy subjects showed no adverse effects and an effective dose of 0.0217 mSv/MBq, enabling multiple scans in a single subject.
Why the study?
Is a single microdose of 18F-FB-A20FMDV2 safe and what is its biodistribution and radiation dosimetry in healthy humans?
Is a single microdose of 18F-FB-A20FMDV2 safe and what is its biodistribution and radiation dosimetry in healthy humans?
18F-FB-A20FMDV2 is safe and has an effective radiation dose that permits multiple PET scans in a single subject for imaging αvβ6 integrin.
Answers are grounded in this paper and cite their sources.
Supports repeated dosing in humans; leaves open validation for αvβ6 imaging in disease.
The αvβ₆ integrin is involved in the pathogenesis of cancer and fibrosis. A radiolabeled 20-amino-acid αvβ₆-binding peptide, derived from the foot and mouth virus (NAVPNLRGDLQVLAQKVART [A20FMDV2]), has been developed to image αvβ₆ levels preclinically. This study was designed to translate these findings into a clinical PET imaging protocol to measure the expression of αvβ₆ in humans. Methods: Preclinical toxicology was undertaken, and a direct immunoassay was developed for 4-fluorobenzamide (FB)-A20FMDV2. Four healthy human subjects (2 male and 2 female) received a single microdose of ¹⁸F-FB-A20FMDV2 followed by a multibed PET scan of the whole body over more than 3 h. Results: There were no findings in the preclinical toxicology assessments, and no anti-A20FMDV2 antibodies were detected before or after dosing with the PET ligand. The mean and SD of the administered mass of ¹⁸F-FB-A20FMDV2 was 8.7 ± 4.4 μg (range, 2.7–13.0 μg). The mean administered activity was 124 ± 20 MBq (range, 98–145 MBq). There were no adverse or clinically detectable pharmacologic effects in any of the subjects. No significant changes in vital signs, laboratory study results, or electrocardiography results were observed. Uptake of radioactivity was observed in the thyroid, salivary glands, liver, stomach wall, spleen, kidneys, ureters, and bladder. Time–activity curves indicated that the highest activity was in the bladder content, followed by the kidneys, small intestine, stomach, liver, spleen, thyroid, and gallbladder. The largest component of the residence times was the voided urine, followed by muscle, bladder, and liver. Using the mean residence time over all subjects as input to OLINDA/EXM, the effective dose was determined to be 0.0217 mSv/MBq; using residence times from single subjects gave an SD of 0.0020 mSv/MBq from the mean. The critical organ was the urinary bladder, with an absorbed dose of 0.18 mGy/MBq. Conclusion:¹⁸F-FB-A20FMDV2 successfully passed toxicology criteria, showed no adverse effects in this first-in-humans study, and has an effective dose that enables multiple scans in a single subject.
No takes yet. Share an insight, caveat, or question.
Keat et al. (2018) studied Healthy (n=4). 18F-FB-A20FMDV2 was evaluated on Safety, immunogenicity, biodistribution, and radiation dosimetry. Administration of 18F-FB-A20FMDV2 in healthy subjects showed no adverse effects and an effective dose of 0.0217 mSv/MBq, enabling multiple scans in a single subject.
Synapse has enriched 10 related papers. Consider them for comparative context: